Targeting Nucleolar Dna Damage Response as a Novel Therapeutic strategy for High Grade Serous Ovarian Cancer

Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer

C Cerra, MRC Tancock, N Thio, A Koo, AR Wong, K J. Cowley, S Varshney, MO Willis, KJ Simpson, DDL Bowtell, E Sanij, EL Christie, RB Pearson, J Kang, KT Chan

2025-01-01

Treatments for high-grade serous ovarian cancer (HGSOC) are initially effective but most invariably fail. Although they can succes..

ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia

K Behrens, N Brajanovski, Z Xu, EM Viney, L DiRago, S Hediyeh-Zadeh, MJ Davis, RB Pearson, E Sanij, WS Alexander, AP Ng

2024-03-01

Philadelphia chromosome–positive B cell acute lymphoblastic leukemia (B-ALL), characterized by the BCR::ABL1 fusion gene, remains ..

Cystathionine-β-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation

H Zhu, KT Chan, X Huang, C Cerra, S Blake, AS Trigos, D Anderson, DJ Creek, DP De Souza, X Wang, C Fu, M Jana, E Sanij, RB Pearson, J Kang

2022-06-01

Hyperactivation of oncogenic pathways downstream of RAS and PI3K/AKT in normal cells induces a senescence-like phenotype that acts..

Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

J Kang, N Brajanovski, KT Chan, J Xuan, RB Pearson, E Sanij

2021-12-01

Ribosome biogenesis and protein synthesis are fundamental rate-limiting steps for cell growth and proliferation. The ribosomal pro..

Harnessing the nucleolar dna damage response in cancer therapy

J Xuan, K Gitareja, N Brajanovski, E Sanij

2021-08-01

The nucleoli are subdomains of the nucleus that form around actively transcribed ribosomal RNA (rRNA) genes. They serve as the sit..

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

J Xuan, RB Pearson, E Sanij

2020-11-01

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the effi..

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461

J Son, KM Hannan, G Poortinga, N Hein, DP Cameron, ARD Ganley, KE Sheppard, RB Pearson, RD Hannan, E Sanij

2020-07-03

Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and ..

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna

2020-05-26

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..